Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-up

Video

Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.

Fred Saad, MD, FRCS, a professor and chairman of Urology, and director of Genitourinary Oncology at the University of Montreal Hospital Center, spoke with CancerNetwork® during the 2022 European Society for Medical Oncology Congress (ESMO) about updated findings from the phase 3 PROpel trial (NCT03732820), assessing abiraterone (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC).

In patients who received first-line abiraterone and olaparib or abiraterone and placebo, the median overall survival (OS) was not reached, having achieved a maturity of 40.1% (NR; HR, 0.83; 95% CI, 0.66-1.03; P = .11). Moreover, he described the benefit patients with BRCA mutations experienced after receiving the regimen.

Transcript:

What the data we presented here adds to what has already been presented and published is that as the data mature, we're seeing that this trend in overall survival [OS] continues to improve. [It] is very reassuring that we're not seeing a disappearance of that [OS] advantage; it’s actually getting better as the data continues to mature. We’re still only at [approximately] 40% of deaths. The median survival has still not been reached in either arm, which is a good thing for patients, but it tells us that we need to have more time for definite answers regarding [OS].

It also adds to our understanding of the importance of patients with or without mutations, especially BRCA mutations. For [those] who are still wondering about the actual benefit, this answers several questions. Clearly, BRCA-mutated patients are getting tremendous benefit.

Reference

Saad F, Armstrong AJ, Thiery-Vuillemin A, et al. 1357O - Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2022;33(suppl 7):S616-S652. doi:10.1016/annonc/annonc1070

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Related Content